HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) shares saw an uptick in trading volume on Thursday . 1,834,385 shares changed hands during mid-day trading, an increase of 156% from the previous session’s volume of 716,025 shares.The stock last traded at $2.09 and had previously closed at $1.90.

A number of brokerages have recently weighed in on HTGM. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of HTG Molecular Diagnostics in a research note on Thursday, June 29th. ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.17.

The stock’s market capitalization is $23.24 million. The firm’s 50 day moving average price is $1.86 and its 200 day moving average price is $1.86.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. Equities analysts predict that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current fiscal year.

In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the stock in a transaction on Friday, August 25th. The stock was sold at an average price of $1.81, for a total value of $2,081,161.53. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 1,659,998 shares of company stock worth $3,073,696 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of HTGM. UBS Group AG purchased a new position in shares of HTG Molecular Diagnostics in the 1st quarter worth $137,000. Two Sigma Securities LLC purchased a new position in shares of HTG Molecular Diagnostics in the 1st quarter worth $150,000. Granahan Investment Management Inc. MA purchased a new position in shares of HTG Molecular Diagnostics in the 1st quarter worth $228,000. Finally, Vanguard Group Inc. raised its position in shares of HTG Molecular Diagnostics by 38.9% in the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares during the period. 21.67% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-sees-unusually-high-trading-volume-2/1629862.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.